1. In Vivo
  2. >>Global Vision

Onyx’s Transformative Year: From Productive Partner To Big Cap Contender?

Onyx Pharmaceuticals is working to execute on two launches and produce late-stage data that will enable it to add more indications to its growing roster of marketed drugs. If it succeeds, it could eventually rival competitor Celgene as one of the few biotechs to move from a small cap into the big cap ranks, but any stumbles could slow or eliminate Onyx’s evolution.

Getting past execution risk is only one step on the road to becoming a sustainable independent big cap. As a company becomes profitable, investors expect it to bring in another substantial revenue-generating candidate. In 2013, execution is the name of the game for Onyx Pharmaceuticals Inc. It’s marketing its first wholly owned product, Kyprolis (carfilzomib), a treatment for refractory multiple myeloma (MM) patients, on its own in the US and major European countries. That’s a tallorder for a mid-cap biotech, but expectations are high, and if it succeeds, the company could become one of a handful of biotechs that evolve from R&D houses into fully integrated biopharmaceutical companies.

Already the company has made significant progress toward that goal; its market cap doubled to $5 billion in 2012. That’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Thinking Outside The BIOX: Bioxodes Takes Novel Approach To Intracerebral Hemorrhage

 
• By Jo Shorthouse

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By David Wild

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.